Department of Psychiatry, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.
Department of Psychiatry, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
J Clin Psychiatry. 2016 May;77(5):e573-9. doi: 10.4088/JCP.15m09898.
To compare the risk of antipsychotic-related seizure (ARS) by identifying seizures first diagnosed within 12 months after starting new antipsychotics, using a 12-year total population health claims database from Taiwan.
Seizure events were identified through emergency department visits or hospitalization with a diagnosis of convulsion (ICD-9-CM: 780.3) or epilepsy (ICD-9-CM: 345). Subjects had an ICD-9-CM diagnosis of schizophrenia, bipolar disorders, or major depressive disorders. Incidence rates of ARS were calculated by person-years of exposure. The ARS risk, adjusted for patient characteristics and medical conditions, of individual antipsychotics versus risperidone was examined by high-dimensional propensity score stratification analyses, followed by sensitivity analyses.
The overall 1-year incidence rate of ARS was 9.6 (95% CI, 8.8-10.4) per 1,000 person-years (550 ARS events among 288,397 new antipsychotic users). First-generation antipsychotics were marginally associated with a higher ARS risk than second-generation antipsychotics (adjusted hazard ratio [aHR] = 1.34; 95% CI, 0.99-1.81; P = .061). Most antipsychotics, first- or second-generation, had comparable ARS risks versus risperidone. Notably, clozapine (aHR = 3.06; 95% CI, 1.40-6.71), thioridazine (aHR = 2.90; 95% CI, 1.65-5.10), chlorprothixene (aHR = 2.60; 95% CI, 1.04-6.49), and haloperidol (aHR = 2.34; 95% CI, 1.48-3.71) had higher ARS risks than risperidone, whereas aripiprazole (aHR = 0.41; 95% CI, 0.17-1.00; P = .050) had a marginally lower ARS risk. Sensitivity analyses largely confirmed such findings.
Higher vigilance for ARS is warranted during use of clozapine, chlorprothixene, thioridazine, and haloperidol. The possible lower ARS risk associated with aripiprazole can be clinically significant but needs to be confirmed by larger-scale systematic studies. The comparative ARS risks of antipsychotics supplement empirical knowledge for making judicious choices in prescribing antipsychotics.
通过识别新使用抗精神病药后 12 个月内首次诊断的癫痫发作,利用来自台湾的 12 年全人群健康理赔数据库,比较抗精神病药相关癫痫发作(ARS)的风险。
通过急诊就诊或住院治疗,以癫痫(ICD-9-CM:780.3)或癫痫(ICD-9-CM:345)的诊断来识别癫痫发作事件。研究对象的 ICD-9-CM 诊断为精神分裂症、双相情感障碍或重度抑郁症。通过人年暴露计算 ARS 的发生率。通过高维倾向评分分层分析,比较个体抗精神病药与利培酮的 ARS 风险,并进行敏感性分析。
整体 1 年 ARS 发生率为每 1000 人年 9.6(95%CI,8.8-10.4)(288397 名新使用抗精神病药患者中有 550 例 ARS 事件)。第一代抗精神病药与第二代抗精神病药相比,癫痫发作风险略高(调整后的危险比[aHR]为 1.34;95%CI,0.99-1.81;P=0.061)。第一代或第二代大多数抗精神病药与利培酮的 ARS 风险相当。值得注意的是,氯氮平(aHR=3.06;95%CI,1.40-6.71)、硫利达嗪(aHR=2.90;95%CI,1.65-5.10)、氯普噻吨(aHR=2.60;95%CI,1.04-6.49)和氟哌啶醇(aHR=2.34;95%CI,1.48-3.71)的 ARS 风险高于利培酮,而阿立哌唑(aHR=0.41;95%CI,0.17-1.00;P=0.050)的 ARS 风险略低。敏感性分析基本证实了上述发现。
在使用氯氮平、氯普噻吨、硫利达嗪和氟哌啶醇时,应更加警惕 ARS。阿立哌唑可能与较低的 ARS 风险相关,但需要更大规模的系统研究来证实。抗精神病药的 ARS 相对风险为合理选择抗精神病药提供了经验性知识补充。